Leerink Partnrs Comments on BPMC FY2027 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Leerink Partnrs issued their FY2027 earnings estimates for shares of Blueprint Medicines in a research note issued on Tuesday, January 14th. Leerink Partnrs analyst A. Berens expects that the biotechnology company will post earnings of $4.98 per share for the year. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.68) per share.

Several other brokerages also recently weighed in on BPMC. Wells Fargo & Company reduced their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. JMP Securities reiterated a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a report on Wednesday. UBS Group began coverage on Blueprint Medicines in a report on Thursday, October 24th. They set a “neutral” rating and a $88.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $122.72.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock opened at $104.89 on Thursday. The firm has a market cap of $6.66 billion, a PE ratio of -49.71 and a beta of 0.61. Blueprint Medicines has a twelve month low of $72.24 and a twelve month high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The business has a 50-day moving average price of $93.75 and a 200 day moving average price of $95.29.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm’s revenue was up 126.5% on a year-over-year basis. During the same quarter last year, the business earned ($2.20) earnings per share.

Hedge Funds Weigh In On Blueprint Medicines

Several large investors have recently modified their holdings of the business. Quarry LP purchased a new stake in shares of Blueprint Medicines in the 3rd quarter valued at approximately $32,000. Covestor Ltd increased its stake in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 403 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Blueprint Medicines during the third quarter worth about $108,000. Values First Advisors Inc. purchased a new position in shares of Blueprint Medicines in the third quarter valued at approximately $122,000. Finally, CWM LLC grew its holdings in shares of Blueprint Medicines by 69.2% in the third quarter. CWM LLC now owns 1,870 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 765 shares in the last quarter.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 1,819 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $93.26, for a total value of $169,639.94. Following the transaction, the insider now directly owns 14,967 shares in the company, valued at $1,395,822.42. The trade was a 10.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kate Haviland sold 2,353 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $96.60, for a total transaction of $227,299.80. Following the sale, the chief executive officer now owns 150,824 shares of the company’s stock, valued at $14,569,598.40. This represents a 1.54 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,970 shares of company stock valued at $2,914,246. 4.21% of the stock is owned by company insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.